Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
952 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01998880 | CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 | clinicaltrials |
| NCT02053610 | CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 2) | completed | Phase 3 | 787 | Hoffmann-La RocheINDUSTRY | 26 | Sep 14, 2018 |
| clinicaltrials |
| NCT00984282 | Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | completed | Phase 3 | 417 | BayerINDUSTRY | 18 | Sep 13, 2018 | clinicaltrials |
| NCT01191801 | Study of Vosaroxin or Placebo in Combination With Cytarabine in Patients With First Relapsed or Refractory AML(VALOR) | completed | Phase 3 | 711 | Sunesis PharmaceuticalsINDUSTRY | 15 | Aug 22, 2018 | clinicaltrials |
| NCT01026142 | A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA) | completed | Phase 3 | 452 | Hoffmann-La RocheINDUSTRY | 23 | Aug 14, 2018 | clinicaltrials |
| NCT00552058 | Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease | completed | Phase 3 | 439 | UCB PharmaINDUSTRY | 20 | Aug 9, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT00333788 | Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease(Welcome2) | completed | Phase 3 | 233 | UCB PharmaINDUSTRY | 12 | Aug 7, 2018 | clinicaltrials |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | completed | Phase 3 | 271 | Millennium Pharmaceuticals, Inc.INDUSTRY | 31 | Jul 31, 2018 | clinicaltrials |
| NCT01767155 | Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer(ZoptEC) | completed | Phase 3 | 511 | AEterna ZentarisINDUSTRY | 22 | Jul 31, 2018 | clinicaltrials |
| NCT01006252 | A Study of Tasisulam-sodium Versus Paclitaxel as Treatment for Metastatic Melanoma(SUMMIT-1) | terminated | Phase 3 | 336 | Eli Lilly and CompanyINDUSTRY | 18 | Jul 17, 2018 | clinicaltrials |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 487 | Millennium Pharmaceuticals, Inc.INDUSTRY | 29 | Jul 12, 2018 | clinicaltrials |
| NCT00003888 | Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 3 | 359 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 15 | Jul 9, 2018 | clinicaltrials |
| NCT00056056 | Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides | terminated | Phase 3 | 93 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 13 | Jul 9, 2018 | clinicaltrials |
| NCT01098656 | Lenalidomide Maintenance Post-debulking in Advanced CTCL | terminated | Phase 3 | 21 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Jul 9, 2018 | clinicaltrials |
| NCT00949650 | BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation | completed | Phase 3 | 345 | Boehringer IngelheimINDUSTRY | 25 | Apr 6, 2018 | clinicaltrials |
| NCT01245062 | GSK1120212 vs Chemotherapy in Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma | completed | Phase 3 | 322 | GlaxoSmithKlineINDUSTRY | 19 | Apr 5, 2018 | clinicaltrials |
| NCT00988208 | Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer(Mainsail) | completed | Phase 3 | 1,059 | CelgeneINDUSTRY | 21 | Apr 4, 2018 | clinicaltrials |
| NCT01605227 | Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100(COMET-1) | completed | Phase 3 | 1,028 | ExelixisINDUSTRY | 14 | Mar 14, 2018 | clinicaltrials |
| NCT01345682 | LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | completed | Phase 3 | 483 | Boehringer IngelheimINDUSTRY | 19 | Feb 15, 2018 | clinicaltrials |
| NCT02119663 | A Study of Ruxolitinib in Pancreatic Cancer Patients | terminated | Phase 3 | 86 | Incyte CorporationINDUSTRY | 14 | Feb 13, 2018 | clinicaltrials |
| NCT01724021 | A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a | completed | Phase 3 | 743 | Hoffmann-La RocheINDUSTRY | 32 | Jan 23, 2018 | clinicaltrials |
| NCT01480479 | Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma(ACT IV) | completed | Phase 3 | 745 | Celldex TherapeuticsINDUSTRY | 24 | Jan 16, 2018 | clinicaltrials |
| NCT01307397 | A Study of Vemurafenib in Participants With Metastatic Melanoma | completed | Phase 3 | 3,219 | Hoffmann-La RocheINDUSTRY | 44 | Dec 18, 2017 | clinicaltrials |
| NCT01015118 | LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer | completed | Phase 3 | 1,366 | Boehringer IngelheimINDUSTRY | 22 | Dec 7, 2017 | clinicaltrials |
| NCT01345669 | LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy | terminated | Phase 3 | 617 | Boehringer IngelheimINDUSTRY | 29 | Dec 7, 2017 | clinicaltrials |
| NCT01281254 | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | terminated | Phase 3 | 223 | AmgenINDUSTRY | 18 | Dec 2, 2017 | clinicaltrials |
| NCT01154140 | A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung(PROFILE 1014) | completed | Phase 3 | 343 | PfizerINDUSTRY | 31 | Nov 6, 2017 | clinicaltrials |
| NCT00424047 | A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma | completed | Phase 3 | 351 | CelgeneINDUSTRY | 15 | Oct 19, 2017 | clinicaltrials |
| NCT00151242 | Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 2 / Phase 3 | 920 | University of UlmOTHER | 2 | Sep 20, 2017 | clinicaltrials |
| NCT01351415 | A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | completed | Phase 3 | 485 | Hoffmann-La RocheINDUSTRY | 18 | Sep 18, 2017 | clinicaltrials |
| NCT00241722 | Long-Term Safety Evaluation Of Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain | completed | Phase 3 | 805 | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 17 | Aug 30, 2017 | clinicaltrials |
| NCT01074047 | Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML) | completed | Phase 3 | 488 | CelgeneINDUSTRY | 18 | Aug 29, 2017 | clinicaltrials |
| NCT02149108 | Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1) | completed | Phase 3 | 768 | Boehringer IngelheimINDUSTRY | 25 | Jul 21, 2017 | clinicaltrials |
| NCT00790036 | Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy(PILLAR2) | completed | Phase 3 | 742 | Novartis PharmaceuticalsINDUSTRY | 34 | Jul 12, 2017 | clinicaltrials |
| NCT01163253 | A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis | terminated | Phase 3 | 2,867 | PfizerINDUSTRY | 36 | Jun 26, 2017 | clinicaltrials |
| NCT01360554 | ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer(ARCHER 1009) | completed | Phase 3 | 878 | PfizerINDUSTRY | 23 | May 24, 2017 | clinicaltrials |
| NCT01684878 | Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE) | completed | Phase 3 | 208 | Hoffmann-La RocheINDUSTRY | 10 | May 23, 2017 | clinicaltrials |
| NCT00428090 | Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease | completed | Phase 3 | 862 | GlaxoSmithKlineINDUSTRY | 20 | May 19, 2017 | clinicaltrials |
| NCT01193244 | Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer | completed | Phase 3 | 1,560 | Millennium Pharmaceuticals, Inc.INDUSTRY | 40 | May 17, 2017 | clinicaltrials |
| NCT01497951 | Photodynamic Therapy for Oral Precursor Lesions(PDT) | completed | Phase 3 | 28 | Medical University of ViennaOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00863655 | Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole(BOLERO-2) | completed | Phase 3 | 724 | Novartis PharmaceuticalsINDUSTRY | 24 | May 2, 2017 | clinicaltrials |
| NCT01302392 | A Study of Carfilzomib vs Best Supportive Care in Subjects With Relapsed and Refractory Multiple Myeloma(FOCUS) | completed | Phase 3 | 315 | AmgenINDUSTRY | 19 | May 2, 2017 | clinicaltrials |
| NCT00045032 | Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer(HERA) | completed | Phase 3 | 5,099 | Hoffmann-La RocheINDUSTRY | 33 | Apr 27, 2017 | clinicaltrials |
| NCT01613846 | Phase III Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma (SWITCH-II) | completed | Phase 3 | 544 | Technical University of MunichOTHER | 3 | Apr 20, 2017 | clinicaltrials |
| NCT00151255 | All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia | completed | Phase 3 | 500 | University of UlmOTHER | 2 | Apr 19, 2017 | clinicaltrials |
| NCT00384176 | First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX(HORIZON III) | completed | Phase 2 / Phase 3 | 1,814 | AstraZenecaINDUSTRY | 28 | Apr 14, 2017 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials